BioSpace News Archive

XenoTherapeutics, a life science company developing the first non-human organ transplant solution currently under investigational review by the FDA, announced that company co-founders Paul Holzer, CEO and Jon Adkins, COO presented an update on the company’s pre-clinical progress for its skin transplant solution at the 2018 Dan Morton Meeting of the Boston Area Pharmaceutical Toxicology Group.

The Equitas Health Institute will host its third annual Transforming Care Conference (TCC) at The Ohio State University - Fawcett Center October 18-19th.

Trans-Hit Bio (THB) is pleased to announce today the signing of an exclusive partnership with Professor Hugo A. Barrera-Saldaña, Founder and General Director of Vitagenesis, the first Mexican biomarker-based diagnostic laboratory. Professor Barrera, through a lifetime of leadership in biomedical translational research, has, in recent years, been concentrating in the promotion of biobanking in top medical research institutions in Mexico.

TraceLink Inc. today announced Smart Rx Manager a solution that enables pharmacists, hospitals, clinics and dispensing doctors to achieve compliance with the verification and decommissioning requirements of the European Union Falsified Medicines Directive (FMD).

The birthplace of the organization, Hyundai Hope On Wheels (HHOW) was proud to return to Boston to be the presenting sponsor of the 2018 Boston Marathon Jimmy Fund Walk, in support of pediatric cancer

Celebrating its 20th year anniversary in the fight against pediatric cancer, Hyundai Hope On Wheels® (HHOW), a 501c(3) non-profit organization, hosted the final stop of its nationwide tour for Childhood Cancer Awareness month in Orange County.

As a pediatric endocrinologist and Medical Director of the Center for Bone Health at Children’s Hospital of Philadelphia (CHOP), Michael A. Levine, MD, specializes in endocrine diseases that affect bone and mineral metabolism, particularly osteoporosis, primary hyperparathyroidism, hypoparathyroidism, rickets and genetic bone disease.

The U.S. Food and Drug Administration today allowed marketing of a new device, the Bose Hearing Aid, intended to amplify sounds for individuals 18 years or older with perceived mild to moderate hearing impairment (hearing loss).

Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Roflumilast Tablets, 500mcg, generic for Daliresp® Tablets by AstraZeneca Pharmaceutical LP.

Direct Orthopedic Care (DOC), an immediate access orthopedic clinic treating pediatric to geriatric orthopedic conditions, announces that Brannon Frank, M.D., will join Direct Orthopedic Care on October 1, 2018